A Mapping of Drug Space from the Viewpoint of Small Molecule Metabolism

James Corey Adams, Michael J. Keiser, Li Basuino, Henry F. Chambers, Deok‐Sun Lee, Olaf Wiest, Patricia C. BabbittPLoS 2009 · DOI

Abstract

Small molecule drugs target many core metabolic enzymes in humans and pathogens, often mimicking endogenous ligands. The effects may be therapeutic or toxic, but are frequently unexpected. A large-scale mapping of the intersection between drugs and metabolism is needed to better guide drug discovery. To map the intersection between drugs and metabolism, we have grouped drugs and metabolites by their associated targets and enzymes using ligand-based set signatures created to quantify their degree of similarity in chemical space. The results reveal the chemical space that has been explored for metabolic targets, where successful drugs have been found, and what novel territory remains. To aid other researchers in their drug discovery efforts, we have created an online resource of interactive maps linking drugs to metabolism. These maps predict the "effect space" comprising likely target enzymes for each of the 246 MDDR drug classes in humans. The online resource also provides species-specific interactive drug-metabolism maps for each of the 385 model organisms and pathogens in the BioCyc database collection. Chemical similarity links between drugs and metabolites predict potential toxicity, suggest routes of metabolism, and reveal drug polypharmacology. The metabolic maps enable interactive navigation of the vast biological data on potential metabolic drug targets and the drug chemistry currently available to prosecute those targets. Thus, this work provides a large-scale approach to ligand-based prediction of drug action in small molecule metabolism.

Introduction

Drug discovery is a high-stakes endeavor often hindered by unforeseen metabolic side effects or a lack of biological context for pathogens. Historically, successful drugs have often been "antimetabolites"—compounds that mimic natural substrates to inhibit essential cellular machinery. However, a comprehensive, global map of these interactions has remained elusive. Traditional methods for target prediction typically require detailed 3D protein structures or genetic sequences. This research proposes a "ligand-centric" alternative: if a drug shares chemical features with a natural metabolite, it is statistically likely to interact with the enzymes associated with that metabolite.

Methodology

The core of this mapping effort is the Similarity Ensemble Approach (SEA), a statistical framework designed to compare sets of molecules rather than individual pairs.

  1. Ligand Set Construction: Molecules were grouped into sets based on metabolic reactions (substrates and products from MetaCyc) and drug classes (known therapeutic targets from the MDL Drug Data Report).
  2. Chemical Fingerprinting: Each molecule was represented by a 2D topological fingerprint (Scitegic ECFP4), capturing its unique bond patterns.
  3. Statistical Scoring: SEA calculates a raw similarity score using the Tanimoto coefficient. This score is then normalized against a background distribution to produce an Expectation value (E-value), indicating the probability that the similarity occurred by chance.
  4. Visualization: These statistical links were mapped onto canonical metabolic pathways from BioCyc and HumanCyc to visualize the "effect space" of various drug classes.
The SEA workflow: composing sets, generating fingerprints, calculating raw scores, and determining statistical significance (E-values).

Key Results and Insights

The large-scale mapping revealed that chemical similarity is a robust predictor of drug-metabolism interactions:

  • Broad Metabolic Intersection: Approximately 54% of the 246 drug classes analyzed exhibited significant chemical similarity (E < 10⁻¹⁰) to at least one metabolic reaction.
  • Target Recovery: The model successfully identified 62 known enzyme targets. In these cases, 61% of the top-scoring hits were either the primary target or an enzyme within the same metabolic pathway.
  • Polypharmacology: The maps highlight that drugs often interact with a "cloud" of enzymes. For example, dihydrofolate reductase (DHFR) inhibitors showed significant similarity to enzymes across 20 different folate-dependent reactions.
  • Pathogen Targeting (MRSA): In a retrospective analysis of Staphylococcus aureus (MRSA), the study identified 39 essential metabolic reactions. By comparing these to human maps, researchers could distinguish between high-risk targets (present in humans) and "cleaner" antibiotic targets unique to the pathogen.

Discussion

This ligand-based approach provides a powerful tool for predicting "off-pathway" hits and potential toxicities. For instance, the discovery that Phospholipase A2 (PLA2) inhibitors share strong similarity with sterol esterase suggests that drugs intended for one system may inadvertently affect another.

However, the method has limitations. It is primarily effective for drugs that mimic substrates or products, potentially missing allosteric inhibitors. Furthermore, the accuracy is contingent on the completeness of underlying databases like MetaCyc. Future work aims to integrate these chemical maps with Flux Balance Analysis (FBA) to move from static predictions to dynamic models of cellular impact.

Summary updated

Abstract

Small molecule drugs target many core metabolic enzymes in humans and pathogens, often mimicking endogenous ligands. The effects may be therapeutic or toxic, but are frequently unexpected. A large-scale mapping of the intersection between drugs and metabolism is needed to better guide drug discovery. To map the intersection between drugs and metabolism, we have grouped drugs and metabolites by their associated targets and enzymes using ligand-based set signatures created to quantify their degree of similarity in chemical space. The results reveal the chemical space that has been explored for metabolic targets, where successful drugs have been found, and what novel territory remains. To aid other researchers in their drug discovery efforts, we have created an online resource of interactive maps linking drugs to metabolism. These maps predict the "effect space" comprising likely target enzymes for each of the 246 MDDR drug classes in humans. The online resource also provides species-specific interactive drug-metabolism maps for each of the 385 model organisms and pathogens in the BioCyc database collection. Chemical similarity links between drugs and metabolites predict potential toxicity, suggest routes of metabolism, and reveal drug polypharmacology. The metabolic maps enable interactive navigation of the vast biological data on potential metabolic drug targets and the drug chemistry currently available to prosecute those targets. Thus, this work provides a large-scale approach to ligand-based prediction of drug action in small molecule metabolism.
BibTeX
@inproceedings{adams2009mapping,
  author = {James Corey Adams and Michael J. Keiser and Li Basuino and Henry F. Chambers and Deok‐Sun Lee and Olaf Wiest and Patricia C. Babbitt},
  title = {{A Mapping of Drug Space from the Viewpoint of Small Molecule Metabolism}},
  booktitle = {PLoS},
  year = {2009},
  doi = {10.1371/journal.pcbi.1000474},
}
Figure